Affymetrix, Inc. (Nasdaq:AFFX) has announced three recipients of the 2015 United States Affymetrix Tumor Profiling Grant Program. The grant program, first launched in 2014, is designed to support translational cancer researchers in the discovery and validation of novel diagnostic, prognostic, and therapeutic biomarkers that may address an unmet clinical need. The qualifying grant projects must use a multi-omics, systems-based approach that analyzes data from multiple molecular and cellular levels to identify robust cancer biomarkers for future application in the clinic. The high level of interest from scientists reflects a growing appreciation of the value of multi-parametric profiling of tumor samples.

The 2015 recipients of the Affymetrix Tumor Profiling Grant Program are:

Dr. Tamara Lotan, MD, Johns Hopkins School of Medicine, Baltimore, MD Molecular profiling to distinguish aggressive from indolent prostate cancer

Dr. Gayle Woloschak, PhD, Northwestern University, Chicago, IL Determination of biomarkers associated with cervical cancer relapse following radiation or chemo-radiation therapy

Dr. Antonia Sepulveda, MD, PhD, Columbia University, New York City, NY Integrated analysis of genomic gene expression alterations for early detection in pancreatic cancer

The recipients are awarded with products from Affymetrix to investigate and combine analysis of at least two different analytes - DNA, RNA, or protein - across 30 tumor samples. The discovery and validation of biomarkers from these projects has the potential to inform better treatment strategies and prognosis prediction, improving overall patient outcome.

"During the second year of our grant program, we continue to see the growing level of interest in using a multi-omics based approach to more rapidly and confidently identify novel cancer biomarkers," says David Weber, Chief Commercial Officer at Affymetrix. "We are eager to partner with the grant recipients and support their project."

Learn more about how Affymetrix' portfolio of solutions for DNA, RNA, protein, and cell analysis can power breakthroughs in cancer research and help translate discoveries into treatments at

About Affymetrix

Affymetrix provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, San Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees and maintains sales and distribution operations worldwide. For more information about Affymetrix, please visit

Forward-looking statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2014, and other SEC reports for subsequent quarterly periods.

PLEASE NOTE: Affymetrix and the Affymetrix logo trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.

View source version on

Copyright Business Wire 2010